Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety and efficacy of Exubera (inhaled insulin) compared with subcutaneous human insulin therapy in children and adolescents ages 6 17 years with type 1 diabetes mellitus: A 12 month, outpatient, randomized, open label, parallel group comparative trial

Trial Profile

Safety and efficacy of Exubera (inhaled insulin) compared with subcutaneous human insulin therapy in children and adolescents ages 6 17 years with type 1 diabetes mellitus: A 12 month, outpatient, randomized, open label, parallel group comparative trial

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 08 Oct 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Insulin (Primary) ; Insulin (Primary)
  • Indications Type 1 diabetes mellitus
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 29 Apr 2010 Additional trial investigator [Rose A] identified as reported by United Kingdom Clinical Research Network record.
    • 29 Apr 2010 New source identified and integrated (United Kingdom Clinical Research Network).
    • 18 May 2008 Status changed from initiated to discontinued as reported by ClinicalTrials.gov. This was a result of Pfizer discontinuing the marketing of Exubera.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top